Stroke: Silotazole is used for secondary prevention of stroke and cognitive decline.

!---- silothoxe is a phosphate terasterase 3' inhibitor that is used in countries in the Asia-Pacific region to prevent stroke, but is rarely used in other regionsin addition to weak antiplatelet action, it stabilizes endothelial cells in laboratory models, contributing to myelin repair and astrocyte-neuron energy transfer, which may help prevent the progression of small vascular disease, researchers systematically evaluated and meta-analyzed non-confused randomized controlled trials of siloata to prevent the progression of stroke, cognitive impairment, or radioactive small blood disease, in a study published in Stroke, the authoritative journal for cardiovascular diseasetwo researchers retrieved the paper (January 1, 2019 to July 16, 2019) and extracted the dataresearchers calculated the Peto ratio (ORs) and 95% CI of recurrent ischemia, hemorrhagic stroke, death, and adverse symptoms through sensitivity analysisthe system review is registered (CRD42018084742)researchers included 20 randomized controlled trials (n-10505), 18 ischemic stroke trials (total n?10449) and 2 cognitive impairment trials (n-56);compared to placebo, aspirin, or clopidogra, silotazole reduced recurrent ischemic stroke (17 trials, n s 10225, OR s.68 (95% CI for 0.57-0.81) ;P,;P,lt;0.0001), hemorrhagic stroke (16 trials, n s9736, 0.43 s.95% CI 29-0.64, ;P,0001), death (OR-0.64 .64 .95% CI is 0.49-0.83), P-lt;0.0009), systemic haemorrhage (n?8387, OR.73.93 CI 0.54-0.99) ;P 0.04), but increased risk of headache, but increased incidence of headachelong-term treatment of silothazole reduces recurrent ischemic stroke, while short-term treatment does not increase bleedingthe data analyzed are insufficient to assess the effects on cognition, imaging, functional outcomes, or toleranceit can be seen that silotha can effectively prevent recurrent stroke in the long term without increasing the risk of bleedinghowever, most trials in patients in the Asia-Pacific region, as well as more trials in Western countries, should assess their effects on cognitive decline, functional outcomes, and tolerance.